Observaciones en el mundo real sobre la efectividad del sistema flash de monitorización de glucosa en la práctica clínica en Chile / Real-world observations of the effectiveness of the flash glucose monitoring in clinical practice in Chile

OBJETIVO: Evaluar el tiempo en rango de glucosa y su asociación con otras medidas del control glicémico establecidas por el consenso internacional del tiempo en rango en usuarios de vida real del sistema flash de monitorización de glucosa FreeStyle LibreTM en Chile. MÉTODOS: Se analizaron los datos provenientes de la base de datos Freestyle Libre™ entre diciembre de 2014 y enero de 2022. Las lecturas se dividieron en 10 grupos (deciles) del mismo tamaño (cada decil contenía aproximadamente 498 usuarios) en función del tiempo en rango. Para cada decil se calculó la media de determinaciones diarias, el promedio de glucosa, la HbA1c, la desviación estándar de glucosa, el coeficiente de variación de la glucosa, el tiempo en rango, el tiempo de glucosa (porcentaje) por encima de 250 mg/dL (TA250), el tiempo de glucosa (porcentaje) por encima de 180 mg/dL (TA180), el tiempo por debajo (porcentaje) de 70 mg/dL (TB70) y el tiempo por debajo (porcentaje) de 54 mg/dL (TB54). RESULTADOS: Desde diciembre de 2014 hasta enero de 2022 hubo 4984 lectores. El grupo con el mayor tiempo en rango mostró significativamente una menor glucosa promedio que el grupo con el tiempo en rango más bajo (decil 1: media 248,3 mg/dL, decil 10: media 113,2 mg/L, diferencia ­135,1 mg/dL, p<0.05). Asimismo, el mayor tiempo en rango se asoció con una menor desviación estándar (decil 1: media 93,7mg/dL, decil 10: media 26,7mg/L, diferencia: -67,0 mg/ dL, p<0,05), menor coeficiente de variación (decil 1: media 37,8%, decil 10: media 23,3%, diferencia: -14,5%, p<0,05), menor TA250 (decil 1: media 46,5%, decil 10: media 0,2%, diferencia: -46,3%, p<0.05), menor TA180 (decil 1: media 73,9%, decil 10: media 3,8%, diferencia: -70,1%, p<0.05), menor TB70 (decil 5: mediana 6,13%, decil 10: mediana 1,70%, diferencia: -4,43%, p<0.05) y menor TB54 (decil 5: mediana 1,79%, decil 10: mediana 0,12%, diferencia: -1,67%, p<0.05). El mayor tiempo en rango se asoció también significativamente con más determinaciones diarias (decil 1: media 11,4, decil 10: media 16,6, diferencia: 5,2, p<0,05). La frecuencia media de las determinaciones entre todos los lectores fue de 14,7 determinaciones diarias. CONCLUSIONES: En los pacientes con diabetes en Chile, el empleo del sistema flash de monitorización demuestra la asociación entre el mayor tiempo en rango, la reducción de la variabilidad de la glucosa y un menor riesgo de hiperglucemias e hipoglicemias y también con un mayor compromiso.

OBJECTIVE: To evaluate glucose time in range and its association with other metrics of glucose control established by the International Consensus on TIR amongst real-life patients using the Flash Glucose Monitoring system FreeStyle LibreTM in Chile. METHODS: Data from the Freestyle Libre™ database between December 2014 and January 2022 were analyzed. Readers were divided into 10 groups (deciles) of the same size (each decile had approximately 498 users) according to time in range. For each decile of time in range, the mean of daily scans, average glucose, estimated HbA1c, glucose standard deviation, glucose coefficient of variation, time in range, glucose time (percentage) above 250 mg/dL (TA250), and glucose time (percentage) above 180 mg/dL (TA180), and the median of glucose time (percentage) below 70 mg/dL (TB70) and glucose time (percentage) below 54 mg/dL (TB54), were calculated. RESULTS: From December 2014 to January 2022, there were 4984 readers. The group with the highest TIR showed significantly lower average glucose than the group with the lowest TIR (decile 1: mean 248.3 mg/dL, decile 10: mean 113.2 mg/L, difference: ­135.1 mg/dL, p<0.05). In addition, more time in range was associated with a lower glucose standard deviation (decile 1: mean 93.7 mg/dL, decile 10: mean 26.7 mg/L, difference: -67.0 mg/dL, p<0.05), lower glucose coefficient of variation (decile 1: mean 37.8%, decile 10: mean 23.3%, difference: -14.5%, p<0.05), lower TA250 (decile 1: mean 46.5%, decile 10: mean 0.2%, difference: -46.3%, p<0.05),lower TA180 (decile 1: mean 73.9%, decile 10: mean 3.8%, difference: -70.1%, p<0.05), lower TB70 (decile 5: median 6.13%, decile 10: median 1.70%, difference: -4.43%, p<0.05) and lower TB54 (decile 5: median 1.79%, decile 10: median 0.12%, difference: -1.67%, p<0.05). Greater TIR was also associated with significantly more daily scans (decile 1: mean 11.4, decile 10: mean 16.6, difference: 5.2, p<0.05). Mean scan frequency amongst all readers was 14.7 daily scans. CONCLUSIONS: In patients with diabetes from Chile, the use of the flash glucose monitoring system demonstrates the association between greater TIR, reduced glucose variability, and reduced risk of hyperglycemia and hypoglycemia, and also its association with greater engagement.

Prevención de diabetes mellitus 2 / Prevention of type 2 diabetes mellitus

La posibilidad de prevenir la Diabetes Mellitus 2 (DM2) se conoce desde hace décadas. Múltiples estudios epidemiológicos han comprobado que los cambios de estilo de vida tienen resultados favorables con costos menores que la propia enfermedad o terapia farmacológica, sin embargo no se ha logrado repetir estos resultados en la población general.Estudios de intervención farmacológica han logrado resultados similares, pero no existe consenso en el uso de ellos, en forma masiva, en etapa pre-diabética. Múltiples factores ambientales han tratado de ser corregidos sin lograrse un éxito que permita incorporarlos como una terapia preventiva eficiente que logre frenar el crecimiento desmedido y las consecuencias de la DM2. Tal vez el completo conocimiento de su condición poligénica permita una terapia realmente anticipada, ya que el conocimiento actual aun no logra establecer el momento en que se inicia el deterioro micro y macroangiopático que caracteriza a la enfermedad

The possibility of preventing the Type 2 Diabetes Mellitus (T2DM) is known for decades. Many epidemiological studies have found that changes in lifestyle have positive results with lower costs, however there has not been possible to repeat these results in the general population. Pharmacological intervention studies have achieved similar results, but there is no consensus on the use of them in pre-diabetes stage. Many environmental factors have tried to be corrected without success. It cannot be incorporated as an efficient preventive therapy to try to stop the growth and the consequences of T2DM. Perhaps the full knowledge of this polygenetic condition will allow an early therapy because current knowledge fails on set the time when start the deterioration of micro and macroangiopatic that characterize this disease

Diabetes mellitus en el paciente con enfermedad renal avanzada / Diabetes mellitus in the chronic renal patient

La diabetes mellitus 2 (DM 2) y la enfermedad renal crónica (ERC) son considerados problemas de salud pública a nivel mundial. Los pronósticos de ambas enfermedades están estrechamente relacionados, por lo que las acciones terapéuticas son complementarias. Un buen control glicémico revierte las alteraciones renales en sus etapas iniciales disminuyendo el deterioro microangiopático y a su vez elintento de obtener un control óptimo de glicemias requiere conocer y tratar las alteraciones provocadas por el ambiente urémico. Es muy importante considerar la existencia de cambios en la interpretación de los análisis de laboratorio, cambios en la farmacocinética y farmacodinamia de los medicamentos hipoglicemiantes e insulinas y finalmente la existencia de dificultades para realizar ejercicios y administrar una alimentación adecuada. Los esquemas de hipoglicemiantes utilizados, tanto medicamentos orales como insulinas, deben ser cuidadosamente personalizados. Se debe evitar la indicación de medicamentos de excreción renal exclusiva por el riesgo de hipoglicemias. Tanto las insulinas análogas como convencionales pueden ser administradas, con precaución en su dosificación y reconociendo la necesidad de un estricto automonitoreo de glicemia digital.

Diabetes Mellitus 2 (DM 2) and the chronic renal disease (CRD) are considered health public problems around the world. The prognoses of both illnesses are narrowly related, so the therapeutic actions are complementary. An appropriate level of glycemia reverses renal alterations in its former stages decreasing the microangiopatic deterioration and, at the same time, the attempt to get an optimal blood sugar control requires to know and treat the alterations caused by the uremic environment. It is very important to consider the existence of changes in the laboratory analyses, the pharmacokinetic and pharmacodynamic changes of the hypoglycemic drugs and insulins and, finally, the existenceof complications to practice physical exercises and to administrate an appropriate nutrition. The hypoglycemic schemes used, whether oral drugs or insulin, must be carefully personalized. It must be avoided excretion renal drug prescriptions, exclusively to avoid hypoglycemic risks. Both analog and conventional insulins can be administrated, being precautious in the dosage and recognizing the needof a strict digital glycemia self-monitoring.

[Small bowel transplantation: Report of a single case]. / Primer trasplante de intestino en Chile: Caso clínico.

Small bowel transplantation is associated with a patient survival at one and five years, of 80% and 63%, respectively. We report a 36 year-old female with short bowel syndrome, subjected to the first small bowel transplantation performed in Chile. A cadaveric gran was used. Immunosuppression was achieved by means of alemtuzumab, tacrolimus, sirolimus, micofenolate mofetil and steroids. Serial endoscopies and biopsies were performed during seven months after transplantation. The most important late complications were a drug induced renal failure, infections caused by opportunistic agents and a gastrointestinal bleeding probably induced by drugs. After 29 months of follow up, the patient is ambulatory, on oral diet only and with no evidence of graft rejection.

Primer trasplante de intestino en Chile: Caso clínico / Small bowel transplantation: Report of a single case

Small bowel transplantation is associated with a patient survival atone and five years, of 80% and 63%, respectively. We report a 36 year-old female with short bowel syndrome, subjected to the first small bowel transplantation performed in Chile. A cadaveric graft was used. Immunosuppression was achieved by means of alemtuzumab, tacrolimus, sirolimus, micofenolate mofetil and steroids. Serial endoscopies and biopsies were performed during sevenmonths after transplantation. The most important late complications were a drug induced renal failure, infections caused by opportunistic agents and a gastrointestinal bleeding probably induced by drugs. After 29 months of follow up, the patient is ambulatory, on oral diet only, and with no evidence of graft rejection.

[A simultaneous study of intestinal permeability and the test of H2 in the expired breath of celiac children]. / Estudio simultáneo de la permeabilidad intestinal y la prueba de H2 en aire espirado en niños celíacos.

Permeability test with sugars (PTS) as a non-invasive diagnostic tool is of special interest in pediatric patients. This study evaluated the relationship between PTS and antigliadin antibodies (AA) with the intestinal biopsy and studied whether an altered expired hydrogen test (EHT) could interfere in this relation in celiac patients. Thirty children (13 girls, 17 boys) with diagnosis of celiac disease (ESPGAN criteria) were divided into three groups according to this histopathology: Group A (n = 23) normal biopsy; Group B (n = 7) biopsy grade III or IV; Group C (n = 25) controls. The intestinal permeability test showed significative differences (p < 0.01) of Group B (0.159 +/- 0.03) with Group A (0.048 +/- 0.005) and with the control Group C (0.039 +/- 0.002). The cut-off for the Youden maximum index (0.75) was 0.092 and ROC SE 0.87 +/- 0.7. The results of the AA were related to those of the PTS. The variance analysis showed that the results of the expired hydrogen test do not interfere statistically on the good correlation of PTS with the histology. The PTS is a good indicator of the status of intestinal mucosa. There is a good correlation between PTS and AA in celiac children. A pathological expired hydrogen test seems not to interfere with the correlation found between PTS and histological damage in our series.

Estudio simultáneo de la permeabilidad intestinal y la prueba de H2 en aire espirado en niños celíacos. / [A simultaneous study of intestinal permeability and the test of H2 in the expired breath of celiac children]

Permeability test with sugars (PTS) as a non-invasive diagnostic tool is of special interest in pediatric patients. This study evaluated the relationship between PTS and antigliadin antibodies (AA) with the intestinal biopsy and studied whether an altered expired hydrogen test (EHT) could interfere in this relation in celiac patients. Thirty children (13 girls, 17 boys) with diagnosis of celiac disease (ESPGAN criteria) were divided into three groups according to this histopathology: Group A (n = 23) normal biopsy; Group B (n = 7) biopsy grade III or IV; Group C (n = 25) controls. The intestinal permeability test showed significative differences (p < 0.01) of Group B (0.159 +/- 0.03) with Group A (0.048 +/- 0.005) and with the control Group C (0.039 +/- 0.002). The cut-off for the Youden maximum index (0.75) was 0.092 and ROC SE 0.87 +/- 0.7. The results of the AA were related to those of the PTS. The variance analysis showed that the results of the expired hydrogen test do not interfere statistically on the good correlation of PTS with the histology. The PTS is a good indicator of the status of intestinal mucosa. There is a good correlation between PTS and AA in celiac children. A pathological expired hydrogen test seems not to interfere with the correlation found between PTS and histological damage in our series.

Estudio simultáneo de la permeabilidad intestinal y la prueba de H2 en aire espirado en niños celíacos. / [A simultaneous study of intestinal permeability and the test of H2 in the expired breath of celiac children]

Permeability test with sugars (PTS) as a non-invasive diagnostic tool is of special interest in pediatric patients. This study evaluated the relationship between PTS and antigliadin antibodies (AA) with the intestinal biopsy and studied whether an altered expired hydrogen test (EHT) could interfere in this relation in celiac patients. Thirty children (13 girls, 17 boys) with diagnosis of celiac disease (ESPGAN criteria) were divided into three groups according to this histopathology: Group A (n = 23) normal biopsy; Group B (n = 7) biopsy grade III or IV; Group C (n = 25) controls. The intestinal permeability test showed significative differences (p < 0.01) of Group B (0.159 +/- 0.03) with Group A (0.048 +/- 0.005) and with the control Group C (0.039 +/- 0.002). The cut-off for the Youden maximum index (0.75) was 0.092 and ROC SE 0.87 +/- 0.7. The results of the AA were related to those of the PTS. The variance analysis showed that the results of the expired hydrogen test do not interfere statistically on the good correlation of PTS with the histology. The PTS is a good indicator of the status of intestinal mucosa. There is a good correlation between PTS and AA in celiac children. A pathological expired hydrogen test seems not to interfere with the correlation found between PTS and histological damage in our series.